Beta is a measure that shows how much a stock moves compared to the overall market. A beta of 1 means the stock usually follows the market trend. A beta below 1 indicates the stock is less volatile, while a beta above 1 means it is more volatile.
Fundamentally strong stocks with a beta less than 1 are considered safer, offering stability during market swings. These stocks reduce portfolio risk while providing consistent long-term returns. For investors seeking steady growth, low-beta stocks create a resilient strategy, balancing stability and performance to navigate economic uncertainties effectively.
Here are a few fundamentally strong small stocks with low volatility and a beta of less than 1
Tata Consultancy Services Limited
With a market capitalization of Rs. 10,51,343.87 crore, the shares of Tata Consultancy Services Limited were currently trading at Rs. 2,905.80 per equity share, down nearly 1.84 percent from its previous day’s close price of Rs. 2,960.35.
Tata Consultancy Services Limited carries a one-year beta of 0.40 and a three-year beta of 0.31, indicating lower volatility compared to the broader market. The company’s ROCE and ROE stand at 64.6 percent and 52.4 percent, respectively. Tata Consultancy Services Limited has an earnings per share (EPS) of Rs. 136, and its debt-to-equity ratio is 0.10x.
Tata Consultancy Services Limited (TCS) was founded in 1968 as a division of Tata Sons Limited and is headquartered in Mumbai. It is a global leader in IT services, consulting, and business solutions. TCS operates in over 46 countries, serving various industries with innovative technology and digital transformation solutions.
Coming into financial highlights, Tata Consultancy Services Limited’s revenue has increased from Rs. 62,613 crore in Q1 FY25 to Rs. 63,437 crore in Q1 FY26, which has grown by 1.32 percent. The net profit has also grown by 5.90 percent from Rs. 12,105 crore in Q1 FY25 to Rs. 12,819 crore in Q1 FY26.
Infosys Limited
With a market capitalization of Rs. 603,612.42 crore, the shares of Infosys Limited were currently trading at Rs. 1,452.95 per equity share, down nearly 2.14 percent from its previous day’s close price of Rs. 1,484.65.
Infosys Limited carries a one-year beta of 0.48 and a three-year beta of 0.48, indicating lower volatility compared to the broader market. The company’s ROCE and ROE stand at 37.5 percent and 28.8 percent, respectively. Infosys Limited has an earnings per share (EPS) of Rs. 65.6, and its debt-to-equity ratio is 0.09x.
Infosys Limited was founded in 1981 by seven engineers in Pune, later relocating its headquarters to Bengaluru. It is a global leader in IT consulting, software services, and outsourcing, serving diverse industries worldwide with innovative technology solutions and digital transformation.
Coming into financial highlights, Infosys Limited’s revenue has increased from Rs. 39,315 crore in Q1 FY25 to Rs. 42,279 crore in Q1 FY26, which has grown by 7.54 percent. The net profit has also grown by 8.63 percent from Rs. 6,374 crore in Q1 FY25 to Rs. 6,924 crore in Q1 FY26.
Hindustan Unilever Limited
With a market capitalization of Rs. 589,747.41 crore, the shares of Hindustan Unilever Limited were currently trading at Rs. 2,510 per equity share, down nearly 1.11 percent from its previous day’s close price of Rs. 2,538.05.
Hindustan Unilever Limited carries a one-year beta of 0.63 and a three-year beta of 0.59, indicating lower volatility compared to the broader market. The company’s ROCE and ROE stand at 27.8 percent and 20.7 percent, respectively. Hindustan Unilever Limited has an earnings per share (EPS) of Rs. 45.9, and its debt-to-equity ratio is 0.03x.
Hindustan Unilever Limited (HUL) was founded in 1933 and is headquartered in Mumbai and is India’s leading FMCG company. It was formed by merging three companies, including Lever Brothers India. HUL offers diverse products in personal care, food, and home care, serving millions across India and globally.
Coming into financial highlights, Hindustan Unilever Limited’s revenue has increased from Rs. 15,707 crore in Q1 FY25 to Rs. 16,514 crore in Q1 FY26, which has grown by 5.14 percent. The net profit has also grown by 5.97 percent from Rs. 2,612 crore in Q1 FY25 to Rs. 2,768 crore in Q1 FY26.
ITC Limited
With a market capitalization of Rs. 507,411.42 crore, the shares of ITC Limited were currently trading at Rs. 405.05 per equity share, rising nearly 1.21 percent from its previous day’s close price of Rs. 400.20.
ITC Limited carries a one-year beta of 0.78 and a three-year beta of 0.79, indicating lower volatility compared to the broader market. The company’s ROCE and ROE stand at 36.8 percent and 27.3 percent, respectively. ITC Limited has an earnings per share (EPS) of Rs. 27.9, and it is almost a debt-free company.
ITC Limited was established in 1910 as the Imperial Tobacco Company of India Limited. Headquartered in Kolkata, it has grown into a diversified conglomerate with businesses spanning FMCG, hotels, paperboards, packaging, agribusiness, and information technology, serving customers across India and beyond.
Coming into financial highlights, ITC Limited’s revenue has increased from Rs. 17,778 crore in Q1 FY25 to Rs. 21,495 crore in Q1 FY26, which has grown by 20.91 percent. The net profit has also grown by 3.21 percent from Rs. 5,177 crore in Q1 FY25 to Rs. 5,343 crore in Q1 FY26.
Sun Pharmaceutical Industries Limited
With a market capitalization of Rs. 380,441.27 crore, the shares of Sun Pharmaceutical Industries Limited were currently trading at Rs. 1,585.65 per equity share, down nearly 2.60 percent from its previous day’s close price of Rs. 1,628.
Sun Pharmaceutical Industries Limited carries a one-year beta of 0.87 and a three-year beta of 0.92, indicating lower volatility compared to the broader market. The company’s ROCE and ROE stand at 20.2 percent and 16.9 percent, respectively. Sun Pharmaceutical Industries Limited has an earnings per share (EPS) of Rs. 43.2, and its debt-to-equity ratio is 0.03x.
Sun Pharmaceutical Industries Limited was founded in 1983 by Dilip Shanghvi in Kolkata. Starting with five psychiatry products and a small team, it expanded into cardiology, neurology, and more. The company grew globally through acquisitions and innovation, becoming India’s largest pharmaceutical firm.
Coming into financial highlights, Sun Pharmaceutical Industries Limited’s revenue has increased from Rs. 12,653 crore in Q1 FY25 to Rs. 13,851 crore in Q1 FY26, which has grown by 9.47 percent. The net profit has decreased by 19.85 percent from Rs. 2,861 crore in Q1 FY25 to Rs. 2,293 crore in Q1 FY26.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
